The effects of oliceridine and sufentanil on postoperative nausea and vomiting in abdominal surgery (EOSPONVAS): protocol for a multicentre, two-arm, randomised controlled trial.

ABSTRACT:

Introduction

Oliceridine is a novel μ-opioid receptor selective agonist that provides analgesia while reducing μ-receptor-mediated adverse effects such as postoperative nausea and vomiting (PONV). Evidence in abdominal surgery remains limited. This study aims to determine whether oliceridine reduces PONV and improves recovery in abdominal surgery.

Methods and analysis

This is a prospective, multicentre, two-arm, randomised trial. Participants aged 18-65 years, with American Society of Anesthesiologists physical status I-III and a body mass index of 18.5-23.9 kg/m², undergoing elective major abdominal surgery, will be eligible for inclusion. Gynaecological surgeries are excluded. All patients must require postoperative intravenous patient-controlled analgesia (PCIA) and give

SUBMITTER: Luo J 

PROVIDER: S-EPMC12506128 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature